NMRA vs. VIR, DNA, TARS, BCRX, FDMT, SANA, AUTL, BEAM, CGEM, and CGON
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Tarsus Pharmaceuticals (TARS), BioCryst Pharmaceuticals (BCRX), 4D Molecular Therapeutics (FDMT), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Beam Therapeutics (BEAM), Cullinan Therapeutics (CGEM), and CG Oncology (CGON). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
Neumora Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -677.69%. Neumora Therapeutics' return on equity of 0.00% beat Vir Biotechnology's return on equity.
Neumora Therapeutics currently has a consensus target price of $22.57, suggesting a potential upside of 137.34%. Vir Biotechnology has a consensus target price of $33.57, suggesting a potential upside of 212.87%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Neumora Therapeutics.
Neumora Therapeutics has higher earnings, but lower revenue than Vir Biotechnology.
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vir Biotechnology received 30 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 48.78% of users gave Vir Biotechnology an outperform vote.
In the previous week, Vir Biotechnology had 8 more articles in the media than Neumora Therapeutics. MarketBeat recorded 12 mentions for Vir Biotechnology and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.24 beat Vir Biotechnology's score of 0.61 indicating that Neumora Therapeutics is being referred to more favorably in the media.
Summary
Neumora Therapeutics beats Vir Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
